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The introduction of second-generation tyrosine-kinase inhibitors (TKIs) has generated a lively debate on the
choice of first-line TKI in chronic phase, chronic myeloid leukemia (CML). Despite the TKIs have different
efficacy and toxicity profiles, the planned use of two TKIs has never been investigated. We report on a
phase 2 study that was designed to evaluate efficacy and safety of a treatment alternating nilotinib and
imatinib, in newly diagnosed BCR-ABL1 positive, chronic phase, CML patients. One hundred twenty-three
patients were enrolled. Median age was 56 years. The probabilities of achieving a complete cytogenetic
response, a major molecular response, and a deep molecular response (MR 4.0) by 2 years were 93%, 87%,
and 61%, respectively. The 5-year overall survival and progression-free survival were 89%. Response rates
and survival are in the range of those reported with nilotinib alone. Moreover, we observed a relatively low
rate of cardiovascular adverse events (5%). These data show that the different efficacy and toxicity profiles
of TKIs could be favorably exploited by alternating their use.
Am. J. Hematol. 91:617–622, 2016. VC 2016 Wiley Periodicals, Inc.
 Introduction
Fifteen years after the introduction of imatinib, at least four other tyrosine kinase inhibitors (TKIs) have become available for the treatment of
Philadelphia chromosome-positive (Ph1), BCR-ABL11, chronic myeloid leukemia (CML) [1–4]. All these TKIs belong to the same class and
share the same target, namely the proteins that are coded by the BCR-ABL1 fusion gene. However, there are several differences among these TKIs,
concerning: the pharmacokinetic profile, the inhibitory efficacy on wild-type or mutated BCR-ABL1 [2,4–7], and, the inhibition of TKs other than
BCR-ABL1 (so-called off–target inhibition) [2,4]. All these differences, influencing the efficacy and safety, suggest that it would have been interest-
ing to test TKIs in combination, similarly to what occurs in many leukemias and cancers, where the sequential or concomitant administration of
effective drugs is common. This was not yet done in CML, where a tradition of single-agent therapy, initiated with spleen radiation and continued
with busulfan, hydroxyurea, and interferon-a, was maintained with TKIs. The investigation of new treatment policies that maintain a high
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therapeutic efficacy, improve the safety profile, and, possibly, have
lower costs, is of utmost importance in CML. In this context, the
high efficacy of nilotinib, and the cardiovascular safety and the lower
cost of imatinib (even more with the upcoming generic formulation)
represent key characteristics that might be interestingly combined.
On this basis, the GIMEMA CML WP designed and conducted a
multicenter, prospective, phase 2 study of a combination of nilotinib
and imatinib, given sequentially for 3-month periods for a minimum
of two years. We report here the final evaluation of this trial, focused
on response rates, safety profile, and outcome.
 Patients and Methods
Study protocol. One hundred and twenty-three adult (18 years old) patients
with newly diagnosed (6 months), chronic phase (CP), Ph1, BCR-ABL11, CML
were enrolled between February and August 2009, at 38 GIMEMA Clinical Centers,
in a phase 2, single-arm study where treatment was initiated with nilotinib, 400 mg
twice daily (BID) for 3 months, then was continued with imatinib, 400 mg once
daily (OD) for other 3 months. Thereafter, the two drugs were given in a rotation
of 3-month periods, for a total of 24 months (core phase of the study). Three days
of drug washout were planned at the end of each 3-month period. During the core
phase, the patients were required to stay on the 2-drugs rotating regime, unless
safety or efficacy issues have occurred. After the first 2 years, physicians were free
to carry on with the 2-drugs rotating regime, or to select between imatinib and
nilotinib; patients were then followed for at least 3 more years (Supporting Infor-
mation Fig. 1). The study (Clinical Trials gov. NCT00769327) was approved by the
Ethics Committees or the Institutional Review Boards of all participating centers,
and was conducted according to Good Clinical Practice and the Declaration of Hel-
sinki. All patients gave written informed consent. Exclusion criteria were a perform-
ance status 2, uncontrolled serious medical conditions, and prior treatment with
TKIs (except for imatinib 30 days). The primary objective of the study was the
evaluation of the 12-month complete cytogenetic response rate. Secondary objec-
tives included the cytogenetic and molecular responses rates during the first 24
months of the study, the analysis of failures, adverse events, and survival.
Definition of risk score and CML phase. The baseline risk score was calculated
according to Sokal [8]. CP, accelerated phase (AP), and blast phase (BP) were
defined according to ELN2. Treatment failures were retrospectively evaluated
according to 2013 ELN recommendations [2].
Cytogenetic response. The cytogenetic response (CyR) was assessed by chromo-
some banding analysis (CBA) of at least 20 marrow cell metaphases, at 3, 6, 9, 12,
18, and 24 months, and defined according to ELN [9]. Fluorescence in situ hybrid-
ization (FISH) on peripheral blood could be used to define the Complete CyR
(CCyR: 1% of BCR-ABL1 positive nuclei over at least 200 nuclei analyzed) [2].
Molecular response. Molecular response (MR) was assessed by RT-PCR of periph-
eral blood cells, at one Center (Bologna) for 2 years, then at GIMEMA Labnet labora-
tories, once they had been standardized, and had received their conversion factor,
allowing the expression of the results according to the International Scale (IS) [10].
Early Molecular Response (EMR) was defined as BCR-ABL1 transcripts level 10% at
3 months. Major Molecular Response (MMR) and MR 4.0 were defined as BCR-ABL1
transcripts 0.1%, and 0.01%, respectively, in samples with more than 10,000 ABL1
copies [11]. Molecular tests were performed every 3 months until a MMR was
achieved and confirmed, then every 6 months. Mutational screening of BCR-ABL1
kinase domain point mutations was performed in case of progression, using conven-
tional Sanger Sequencing, as reported elsewhere [12].
Adverse events. We analyzed the adverse events (AEs) occurred during the first year
of study to correlate their frequency, recurrence, and severity with the TKI that was
taken when the AE occurred. If an AE persisted for more than 15 days after the planned
change of treatment, the AE was associated with both drugs. Among AEs, particular
attention was given to arterial thrombotic/sclerotic events (ATEs), which were defined
as peripheral arterial obstructive disease (PAOD), acute coronary syndrome (acute myo-
cardial infarction [MI]; instable angina), chronic ischemic heart disease (stable angina),
significant carotid stenosis and ischemic stroke.
Statistical analysis. The rate of cytogenetic and molecular response is reported
both “at” a time point, calculated dividing the number of patients with that
response at that time point by the number of all enrolled patients (not evaluable
patients, for any reason, were considered as non-responders), and “by” a time
point, calculated by the Kaplan and Meier method as the cumulative incidence or
probability of having achieved that response within that time period. It is acknowl-
edged that the latter calculation overestimates the response, but this value allows a
comparison, though indirect, with many other studies, where the response rates
were reported only, or mainly, “by” a time point.
Overall survival (OS) and progression-free survival (PFS) were calculated from
the first day of treatment to death by any cause (OS), including death after alloge-
neic stem cell transplantation (SCT), and to progression or death, whichever came
first (PFS), by the method of Kaplan and Meier [13].
 Results
Patients
Baseline characteristics of patients are shown in Supporting Infor-
mation Table I. Males were 52%. Noteworthy is the median age of
56 years, corresponding to the age that was found in population-
based studies in Italy and in Europe[14]. The proportion of Sokal
Figure 1. Cumulative incidence of major molecular response and of MR
4.0 (A), and five-year survival (B, C). Major molecular response (MMR):
BCR-ABL10.1%; ABL copies 10,000. Deep molecular response (MR 4.0):
BCR-ABL10.01%; ABL copies 10,000. Events considered for overall-sur-
vival: deaths for any cause; for progression-free survival: progression to
accelerated/blast phase, and deaths for any cause.
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high-risk patients (22%) was as expected[14]. The median follow-up
of living patients was 60 months (range 54 to 67 months).
Cytogenetic and molecular response
The rates of cytogenetic and molecular response are shown in
Table I. At the end of the first period of nilotinib treatment
(3 months), 91% of patients had achieved the EMR. In 2008 the
prognostic impact of EMR was not yet recognized, thus, according to
protocol, treatment was not changed in the 11 (9%) patients without
EMR. Notably, 2 of them subsequently progressed to BP, and only 3
achieved a MMR. The complete cytogenetic response rate at 12
months was 75%. At the end of the core phase (24 months), 63% of
patients were in CCyR, 54% in MMR, and 44% in MR 4.0 (for all cal-
culations, non evaluable patients were considered as non-responders).
The cumulative incidences by 24 months of CCyR, MMR, and MR4.0
were 93%, 87%, and 61%, respectively. Thereafter, these rates did not
change significantly, with a plateau from the third year on (Fig. 1).
The MMR rate by 24 months was significantly lower for Sokal high-
risk patients compared to intermediate and low risk ones (96%, 90%,
and 69%, respectively; P5 0.005); moreover, high-risk and intermedi-
ate risk patients had lower MR 4.0 rates compared to low risk
patients (55% vs. 73%, respectively; P5 0.016).
Patient disposition and outcome
Patient disposition at the end of the core phase (24 months) and at
the end of study (60 months) is shown in Table II. One hundred and
three patients (84%) were still on study at month 24, with 83/123
(67%) still on the 2-drug rotation regime. Eighty-five patients (69%)
were on study at month 60, but only 14/123 (11%) were on the rota-
tion regime, while 44/123 (36%) had chosen to continue with nilotinib
alone, 300 mg BID, and 27/123 (22%) with imatinib alone. Dasatinib
was the most frequent second-line drug (14% of patients). The 5-year
PFS and OS was 89% (95% CI: 82-94%) (Fig. 1). Overall, 6 patients
were submitted to allogeneic SCT, 4 of them after progression to BP
(all died after SCT, with active disease), and 2 in CP, after failure of
second-line treatment (one died of SCT, one is alive and in remission).
Seven patients (6%) progressed to BP, of whom 4, suddenly, with a
lymphoid phenotype, and 3, through an AP, with a myeloid pheno-
type (Supporting Information Table II). Five of seven progressions
occurred during the first year. Notably, 5/7 had previously achieved
the EMR. All four patients with a lymphoid phenotype had a muta-
tion vs. none of the 3 patients with a myeloid phenotype.
Overall, 13/123 patients (11%) died, of whom 7 after progression
to BP and with active disease, one after SCT in CP, 2 of other malig-
nancies (prostate cancer, 68 years old, after 20 months of therapy;
bladder cancer, 77 years old, after 4 months of therapy), one of a
massive pulmonary embolism (deep vein thrombosis secondary to
pelvic fracture), one of a cerebral hemorrhage with thrombocytopenia
(27x109/L) during the 3rd month of the first nilotinib period, and
one of ischemic stroke at 81 years of age, 54 months after diagnosis,
while on dasatinib treatment (off-study for failure at 24 months)
(Supporting Information Table III).
Adverse events
Non-hematologic adverse events (AEs) and laboratory abnormal-
ities are listed in Table III, Supporting Information Table IV, and
Supporting Information Figs. 2 and 3. During the first year, 256 AEs
were observed: 42% associated with nilotinib (first and/or third quar-
ter), 31% with imatinib (second and/or fourth quarter), and 27% with
both drugs. Moreover, 64% of the AEs were limited to one quarter,
mainly the first, as expected.
The most common AEs were periorbital edema (31.7% of the
patients, all grade 1/2), skin rash (30.7% all grades, 1.6% grade 3),
muscle pain/cramps (26% all grades; 2.4% grade 3), and fatigue
(21.1% all grades; 0.8% grade 3). Periorbital edema was more fre-
quently associated with imatinib, although during nilotinib treatment
it did not completely resolve, or persisted for> 15 days, in 9.8% of
the patients. Skin rash was more common with nilotinib, but, simi-
larly, during imatinib treatment it did not completely resolve, or per-
sisted for> 15 days, in 8.1% of patients.
ATEs were reported in 6 patients (5%) (Supporting Information
Table V). Three patients (age 70, male; age 78, female; age 89, female)
developed a myocardial infarction, which was managed with percuta-
neous trans-luminal angioplasty (two patients), or medical treatment
(one patient). All these 3 patients permanently discontinued nilotinib.
A patient (age 75, female) was diagnosed of unstable angina, which
was managed with medical treatment, and resumed the alternating
TABLE I. Cytogenetic and Molecular Response During the Core Phase of the Study (24 Months)
3 mo % 6 mo % 9 mo % 12 mo % 18 mo % 24 mo %
CCyR ata 70 79 NA 75 65 63
CCyR byb 70 85 NA 91 91 93
EMR ata 91 NA NA NA NA NA
MMR byb 27 45 54 72 87 87
MR 4.0 ata 10 13 15 23 43 44
MR 4.0 byb 10 19 29 39 60 61
a The rates “at” were calculated by dividing the number of patients with that response at that time point by the number of all enrolled patients (n5 123); not
evaluable patients (for any reason) were considered as non-responders.
b The rates “by” express the cumulative probability of achieving that response over that time period.
CCyR, no Ph1 metaphases out of at least 20 marrow cell metaphases or FISH 1% BCR-ABL positive nuclei over at least 200 nuclei analyzed; EMR, BCR-
ABL1 10% at 3 months; MMR, Major Molecular Response (BCR-ABL10.1%); ABL copies 10,000; MR 4.0, BCR-ABL10.01%; ABL copies 10,000; NA, not
applicable.
TABLE II. Patients’ Disposition
End of core phase
(24 months) n (%)
End of study
(60 months) n (%)
On study 103 (84) 85 (69)
On rotation schedule 82 (67) 14 (11)
On nilotinib alone 9 (7) 44 (36)
On imatinib alone 12 (10) 27 (22)
Off-studya 20 (16) 38 (31)
Dead 7 (6) 13 (11)
On dasatinib 8 (7) 16 (13)
On other treatments 4 (3) 4 (3)
Alive after ASCT 0 1
Off treatment 0 1
Lost to follow-up 1 3 (2)
a Off-study: includes the patients who discontinued both study drugs, for
any reason.
ASCT, Allogeneic Stem Cell Transplantation.
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regime. Another patient (age 70, male) complained of worsening clau-
dication, which was controlled with medical treatment, but prompted
the discontinuation of nilotinib. One asymptomatic patient (age 59,
male) developed a carotid stenosis, of moderate grade but progres-
sively worsening, and discontinued nilotinib.
 Discussion
The results of the treatment of newly diagnosed, CP, CML with a
standard dose of imatinib (400 mg OD), together with second- and
third-line treatment with second generation TKIs, in case of failure,
non-optimal response, intolerance or toxicity, are already excellent
[1–4], and few space is left for improvement. The combination of
TKIs with interferon-a or other agents has been recently discussed
[15,16], but currently, with the exception of interferon-a, the efforts
to improve the outcome focus on a larger use of second generation
TKIs in first-line, as well as on an early switch from imatinib to sec-
ond generation TKIs [17–25]. It was reported that these policies
resulted in a faster achievement of more and deeper molecular
responses, in a marginal improvement of PFS, but not of OS. The
obstacles to an earlier and larger use of nilotinib are cost [26] and
toxicity, particularly the concern of vascular complications [27–34].
On the contrary, the cardiovascular safety of imatinib, together with
its lower cost, particularly with the upcoming generic formulation,
may consolidate its use as first-line treatment for the majority of
CML patients. So far, no attempts were made to investigate the use of
TKIs in combination, as it is the case in many leukemias and cancers,
where the sequential or concomitant administration of effective drugs
is common, and beneficial.
When nilotinib became available for the second-line treatment of
CML, we considered that a combination of nilotinib and imatinib
could have been more effective than imatinib alone, and maybe as
effective as nilotinib alone, but less toxic and less expensive. The con-
comitant administration of two TKIs may raise pharmacodynamics
and pharmacokinetics issues impacting on safety, efficacy, dosing, and
schedule. The sequential administration of two TKIs could avoid these
issues, and therefore may be preferable. We selected the 3-month rotat-
ing schedule considering pharmacokinetics aspects (some days are
required to reach a steady-state plasma drug concentration), and taking
care of designing a schedule that would have been easy to comply
with, and that coincided with the routine molecular monitoring.
The standard, approved dose of nilotinib first-line is now 300 mg
BID. However, when this study was designed, in 2008, the tested dose
of nilotinib in second-line was 400 mg BID, and the results of the
ENESTnd study were not yet available [35]; therefore, the dose of
400 mg BID was selected.
In our trial, the cumulative incidence of CCyR by 12 months was
91%, and the cumulative incidences of MMR and MR 4.0 by 24
months were 87% and 61%, respectively. Though any comparison
among different studies is biased, the MMR (Supporting Information
Table VI) and the MR 4.0 rates achieved in this trial were at the
high-end of those reported so far with single-agent TKI [35–49]. Risk
distribution can affect the response: here, the proportion of high
Sokal risk patients was 22%, vs. 16% to 29% in other studies. After
the 24-month core phase, all patients were allowed to move from the
2-drug rotation regime to single drug treatment based on a physi-
cian’s choice. All patients were then followed until a minimum of 5
years, a follow-up that is equal to, or longer than, that of the majority
of the studies of second-generation TKIs in first-line. At 5 years, 69%
of the patients were on treatment with the study drugs, although only
a minority (11%) was still on the rotation regime. Several reasons,
including the selection of the best tolerated drug between imatinib
and nilotinib, the level of molecular response achieved, the success of
the ENESTnd study [35,37], and costs, may have influenced the deci-
sion to continue nilotinib or imatinib alone (36 and 22% of the
patients, respectively).
The 5-year PFS and OS were 89%, an outcome that is in the range
of what reported in prior trials (Supporting Information Table VI)
with TKIs in first-line. Moreover, these results are particularly signifi-
cant if we consider the impact of age on survival [50]. Indeed, in our
study patients’ median age (56 years) was almost 10 years higher
than that of the ENESTnd study (46 and 47 years in imatinib and
nilotinib arms, respectively) [35] and the DASISION study (49 and
46 years in imatinib and dasatinib arms, respectively) [40], and,
importantly, it was close to that reported in population based Regis-
tries in Italy and Europe [14]. Age is also associated to an increased
incidence of arterial thrombotic events; here, despite the significantly
higher median age compared to the ENESTnd study, the rate of arte-
rial thrombotic events was 5%, similar to that reported in the niloti-
nib 300 mg BID arm (7.5%), and lower than that reported in the
nilotinib 400 mg BID arm of that study (13.4%) [39].
TABLE III. Adverse Events Observed During the First Year of Study, According to Treatment (Nilotinib Only, Imatinib Only, Both Nilotinib and Imatinib)
Ascribed to nilotinib Ascribed to imatinib Ascribed to both TKIs Total
All Grades % Grades 3/4% All grades % Grades 3/4 % All grades % Grades 3/4 % All grades % Grades 3/4 %
Periorbital edema 2.4 0 19.5 0 9.8 0 31.7 0
Skin rash 21.1 1.6 1.6 0 8.1 0 30.9 1.6
Muscle pain/cramps 5.7 0 8.9 0 11.4 2.4 26.0 2.4
Fatigue 9.8 0 2.4 0.8 8.9 0 21.1 0.8
Pruritus 13 1.6 0.8 0 4.1 0.8 17.9 2.4
Abdominal pain/diarrhea 5.7 1.6 6.5 0 3.3 0 15.4 1.6
Fluid retentiona 2.4 0 9.8 1.6 1.6 0 13.8 1.6
Bone pain/Joint pain 9.8 0.8 0.8 0.8 1.6 0.8 12.2 2.4
Conjunctivitis/Dry eye 4.1 0 4.9 0.8 2.4 0 11.4 0.8
Gastric pain 6.5 2.4 1.6 0 0.8 0.8 8.9 3.3
Nausea/Vomiting 2.4 0 2.4 0 2.4 0 7.3 0
Headache 4.9 0 0.8 0 0.8 0 6.5 0
Alopecia 2.4 0 2.4 0 0.8 0 5.6 0
a Other than periorbital edema.
Percentage of patients with AEs. We reported here the AEs (all grades) with a cumulative incidence 5% by 12 months, considering all 123 enrolled patients.
We analyzed whether an AE was observed in the same patient during more treatment periods. Therefore, AEs were divided in three groups: AEs ascribed to
nilotinib only, to imatinib only, or to both drugs. If a pre-existing AE persisted for more than 15 days after the planned change of treatment, the AE was asso-
ciated with both drugs.
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Noteworthy, five of seven progressions occurred within the first
year, including 2 patients that had not previously achieved an EMR
(BCR-ABL1 10% at 3 months). It is possible that a prolongation of
the first period of nilotinib could have been useful, particularly in the
patients without EMR. Overall, 12 (10%) patients developed a second-
ary resistance (loss of a previous achieved level of response; details in
Supporting Information Table VII); however, since mutations were
identified in 2 patients only, and conferred resistance to both niloti-
nib and imatinib, it is likely that the rotation of the drugs did not
play a major role in these events.
In summary, this study showed long-term outcomes and molecular
responses fully comparable to those reported in previously published
trials with first-line TKIs in CP CML. The safety data, particularly
concerning cardiovascular adverse events, suggest that the alternating
regime could be safer than nilotinib alone. Moreover, even if a
detailed cost analysis was not planned in this study, it is conceivable
that this policy may result in lower costs compared to nilotinib alone.
We conclude that in newly diagnosed, CP, CML patients the initial
treatment with this 2-TKI rotation regime may be an alternative to
single-TKI therapy.
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